Victor Sandor

Victor Sandor

UNVERIFIED PROFILE

Are you Victor Sandor?   Register this Author

Register author
Victor Sandor

Victor Sandor

Publications by authors named "Victor Sandor"

Are you Victor Sandor?   Register this Author

20Publications

920Reads

35Profile Views

Encorafenib, Binimetinib, and Cetuximab in V600E-Mutated Colorectal Cancer.

N Engl J Med 2019 10 30;381(17):1632-1643. Epub 2019 Sep 30.

From the University of Texas M.D. Anderson Cancer Center, Houston (S.K., V.M.); West Cancer Center and Research Institute, OneOncology, Germantown, TN (A. Grothey); Memorial Sloan Kettering Cancer Center, New York (R.Y., A.K.); University Hospital Gasthuisberg and University of Leuven, Leuven, Belgium (E.V.C., J. Dekervel); the Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (J. Desai, C.G.); National Cancer Center Hospital East, Kashiwa, Japan (T.Y.); Hammersmith Hospital, Division of Cancer, Imperial College London (H.W.), and the Sarah Cannon Research Institute and University College London Cancer Institute (H.-T.A.), London, and the Christie NHS Foundation Trust/National Institute for Health Research Manchester Biomedical Research Centre, Manchester (M.B.) - all in the United Kingdom; the University of Campania Luigi Vanvitelli, Naples (F.C.), and Istituto Oncologico Veneto, Istituto di Ricovero e Cura a Carattere Scientifico, Padua (F.L., S.L.) - both in Italy; Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea (Y.S.H., T.-W.K.); the Netherlands Cancer Institute, Amsterdam (N.S., J.H.M.S.); Oslo University Hospital, Oslo (T.K.G.); Hospital Gregorio Marañón, Madrid (P.G.-A., A.C.F.), and Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, UVic, IOB-Quiron, Barcelona (E.E., J.T.) - both in Spain; Odense University Hospital, Odense, Denmark (P.P., L.S.T.); Pavlov First St. Petersburg State Medical University, St. Petersburg, Russia (S.O.); and Array BioPharma, Boulder, CO (A. Gollerkeri, C.K., K.M., M.P., J.C.-B., L.A., V.S.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1908075DOI Listing
October 2019

Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed.

J Clin Oncol 2015 Dec 8;33(34):4039-47. Epub 2015 Sep 8.

Herbert I. Hurwitz, Duke University Medical Center, Durham, NC; Nikhil Uppal, New York University Langone Arena Oncology, Lake Success, NY; Stephanie A. Wagner, Indiana University Melvin and Bren Simon Cancer Center; Robert Manges, Investigative Clinical Research of Indiana, Indianapolis, IN; Johanna C. Bendell, Sarah Cannon Research Institute, Nashville, TN; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Seaborn M. Wade III, Virginia Cancer Institute, Richmond, VA; John J. Nemunaitis, Mary Crowley Medical Research Center, Dallas, TX; Philip J. Stella, St Joseph Mercy Health System, Alexander Cancer Care Center, Ann Arbor, MI; J. Marc Pipas, Dartmouth Hitchcock Medical Center/Norris Cotton Cancer Center, Lebanon, NH; Zev A. Wainberg, University of California, Los Angeles, Los Angeles, CA; and William M. Garrett, Deborah S. Hunter, Jason Clark, Lance Leopold, Victor Sandor, and Richard S. Levy, Incyte Corporation, Wilmington, DE.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/early/2015/09/03/JCO.2015.61
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2015.61.4578
Publisher Site
http://dx.doi.org/10.1200/JCO.2015.61.4578DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5089161PMC
December 2015

Cdc25A-inhibitory properties and antineoplastic activity of bisperoxovanadium analogues.

Mol Cancer Ther 2003 Oct;2(10):1053-9

Lady Davis Institute for Medical Research, SMBD Jewish General Hospital, Montreal, Quebec, Canada.

View Article

Download full-text PDF

Source
October 2003